Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Abstract Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhi...

Descripción completa

Detalles Bibliográficos

Autores principales:	Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2024-03-01
Colección:	Experimental Hematology & Oncology
Materias:	Cyclin-dependent kinase (CDK) inhibitors Palbociclib BCL2 Venetoclax RB1 Mantle cell lymphoma (MCL)
Acceso en línea:	https://doi.org/10.1186/s40164-024-00499-2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!